Identification of potential surrogate end points in randomized clinical trials of aggressive and indolent non-Hodgkin's lymphoma: correlation of complete response, time-to-event and overall survival end points - Annals of Oncology
Are progression-free and disease-free survival the new gold standard for cancer trials? | Cancer World Archive
Non-anthracycline-containing docetaxel and cyclophosphamide regimen is associated with sustained worse outcome compared with docetaxel, anthracycline and cyclophosphamide in neoadjuvant treatment of triple negative and HER2-positive breast cancer ...
Relationship between presarcopenia and event occurrence in patients with primary hepatocellular carcinoma | Scientific Reports
Identification of potential surrogate end points in randomized clinical trials of aggressive and indolent non-Hodgkin's lymphoma: correlation of complete response, time-to-event and overall survival end points - Annals of Oncology
![Figure 5. [Event-free survival and overall survival...]. - Wilms Tumor - NCBI Bookshelf](https://www.ncbi.nlm.nih.gov/books/NBK373367/bin/fig7_5.jpg "Figure 5. [Event-free survival and overall survival...]. - Wilms Tumor - NCBI Bookshelf")
Figure 5. [Event-free survival and overall survival...]. - Wilms Tumor - NCBI Bookshelf
Event-free and overall survival following neoadjuvant weekly paclitaxel and dose-dense AC +/- carboplatin and/or bevacizumab in triple-negative breast. - ppt download
Statistical considerations and endpoints for clinical lung cancer studies: Can progression free survival (PFS) substitute overall survival (OS) as a valid endpoint in clinical trials for advanced non-small-cell lung cancer? | Semantic
Blood and tissue biomarker analysis in dogs with osteosarcoma treated with palliative radiation and intra-tumoral autologous natural killer cell transfer | PLOS ONE
View Image
A) Event-free survival (EFS), (B) disease-free survival (DFS), and (C)... | Download Scientific Diagram
Frontiers | Evaluation of Event-Free Survival Surrogating Overall Survival as the Endpoint in Neoadjuvant Clinical Trials of Gastroesophageal Adenocarcinoma
Event-free survival > Overall survival? - data analysis - Datamethods Discussion Forum
Kaplan-Meier curve for overall survival (OS) and event-free survival (EFS) according to the expression of CD30 and IPI.
Wilms tumour event-free and overall survival in Southern and Eastern Europe: Pooled analyses of clinical data from four childhood cancer registries (1999–2017) - European Journal of Cancer
Frontiers | Evaluation of Event-Free Survival Surrogating Overall Survival as the Endpoint in Neoadjuvant Clinical Trials of Gastroesophageal Adenocarcinoma
OP0294 SJÖGREN'S SYNDROME ASSOCIATED LYMPHOMAS: CLINICAL DESCRIPTION AND 10-YEAR SURVIVAL | Annals of the Rheumatic Diseases
![Fig. 72.1, [Four-year event-free survival (EFS), overall...]. - The EBMT Handbook - NCBI Bookshelf](https://www.ncbi.nlm.nih.gov/books/NBK553933/bin/978-3-030-02278-5_72_Fig1_HTML.jpg "Fig. 72.1, [Four-year event-free survival (EFS), overall...]. - The EBMT Handbook - NCBI Bookshelf")
Fig. 72.1, [Four-year event-free survival (EFS), overall...]. - The EBMT Handbook - NCBI Bookshelf
Cureus | Does Timing of Completion Radical Cholecystectomy Determine the Survival Outcome in Incidental Carcinoma Gallbladder: A Single-Center Retrospective Analysis
A prognostic nomogram for event-free survival in patients with atrial fibrillation before cardiac resynchronization therapy | BMC Cardiovascular Disorders | Full Text
New Prediction Model for 5-year Event-free Survival Rate from Ventricular Arrhythmia | Radcliffe Cardiology
JCI - Umbilical cord blood expansion with nicotinamide provides long-term multilineage engraftment
Progression-free survival (PFS), event-free survival (EFS), and overall... | Download Scientific Diagram
Event-free survival and overall survival (A) Event-free survival for... | Download Scientific Diagram
Relationship between event-free survival and overall survival in acute myeloid leukemia: a report from SWOG, HOVON/SAKK, and MRC/NCRI | Haematologica
Acute myeloid leukemia: survival analysis of patients at a university hospital of Paraná | Hematology, Transfusion and Cell Therapy
